Digital Content 
NEWS #PharmaBuzz
22 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-showcases-phase-4-data-demonstrating-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-treatment-effects-and-real-world-evidence-at-world-sleep-and-psych-congresses-302562421.html
09 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-presents-late-breaking-phase-4-data-showcasing-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-treatment-outcomes-in-narcolepsy-at-sleep-2025-302476849.html
31 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-presents-new-data-at-psych-congress-2024-confirming-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-treatment-benefits-in-narcolepsy-and-idiopathic-hypersomnia-302293081.html
24 Jul 2024
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-24-2024-12306.pdf
01 Jun 2022
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-01-2022-1654158193.pdf
03 Jan 2022
// BIOSPACE
https://www.biospace.com/article/releases/u-s-fda-grants-orphan-drug-exclusivity-ode-for-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-idiopathic-hypersomnia-in-adults/
Share 